Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03675308




Registration number
NCT03675308
Ethics application status
Date submitted
12/09/2018
Date registered
18/09/2018

Titles & IDs
Public title
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
Scientific title
A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)
Secondary ID [1] 0 0
2017-002465-22
Secondary ID [2] 0 0
M16-011
Universal Trial Number (UTN)
Trial acronym
KEEPsAKE 1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Psoriatic Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Placebo
Treatment: Other - Risankizumab

Placebo comparator: Placebo - Participants randomized to receive double-blind placebo at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive 150 mg risankizumab followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.

Experimental: Risankizumab - Participants randomized to receive 150 mg risankizumab administered by subcutaneous injection at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive blinded placebo followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.


Treatment: Other: Placebo
Placebo for risankizumab administered by subcutaneous injection

Treatment: Other: Risankizumab
Risankizumab administered by subcutaneous injection

Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24
Assessment method [1] 0 0
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:

1. = 20% improvement in 68-tender joint count;
2. = 20% improvement in 66-swollen joint count; and
3. = 20% improvement in at least 3 of the 5 following parameters:

* Physician global assessment of disease activity
* Patient global assessment of disease activity
* Patient assessment of pain
* Health Assessment Questionnaire - Disability Index (HAQ-DI)
* High-sensitivity C-reactive protein (hsCRP).
Timepoint [1] 0 0
Baseline and Week 24
Secondary outcome [1] 0 0
Change From Baseline In Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24
Assessment method [1] 0 0
The Health Assessment Questionnaire Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.

A negative change from Baseline in the overall score indicates improvement.
Timepoint [1] 0 0
Baseline and Week 24
Secondary outcome [2] 0 0
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 Response at Week 24
Assessment method [2] 0 0
PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked).

The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from Baseline in PASI score.
Timepoint [2] 0 0
Baseline and Week 24
Secondary outcome [3] 0 0
Percentage of Participants With an ACR20 Response at Week 16
Assessment method [3] 0 0
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:

1. = 20% improvement in 68-tender joint count;
2. = 20% improvement in 66-swollen joint count; and
3. = 20% improvement in at least 3 of the 5 following parameters:

* Physician global assessment of disease activity
* Patient global assessment of disease activity
* Patient assessment of pain
* Health Assessment Questionnaire - Disability Index (HAQ-DI)
* High-sensitivity C-reactive protein (hsCRP).
Timepoint [3] 0 0
Baseline and Week 16
Secondary outcome [4] 0 0
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24
Assessment method [4] 0 0
A participant was classified as achieving MDA if 5 of the following 7 criteria were met:

* Tender joint count (out of 68 joints) = 1
* Swollen joint count (out of 66 joints) = 1
* PASI score = 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis = 3%
* Patient's assessment of pain = 15 (VAS from 0 to 100)
* Patient's Global Assessment of disease activity = 20 (VAS from 0 to 100)
* HAQ-DI score = 0.5 (index score ranges from 0 to 3)
* Leeds Enthesitis Index = 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, for an overall score range from 0 to 6)
Timepoint [4] 0 0
Week 24
Secondary outcome [5] 0 0
Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 24
Assessment method [5] 0 0
The investigator assessed each fingernail for onycholysis (separation of the nail plate from the nail bed) and oil-drop (salmon patch) dyschromia (reddish-brown discoloration under the nail plate) on a scale of 0 (none present) to 3 (\>30% of the nail), pitting (small, sharply defined depressions in the nail surface) on a scale of 0 (0 pits present) to 3 (\> 50 pits present), and nail plate crumbling on a scale of 0 (no crumbling) to 3 (\>50% of nail has crumbling) and presence (1) or absence (0) of leukonychia (white spots), splinter hemorrhages, nail bed hyperkeratosis, and red spots in the lunula.

The mNAPSI score is calculated as the sum of all the components for all of the participant's fingernails giving a range of possible scores from 0 (absence of nail psoriasis) to 130 (the most severe nail psoriasis). A negative change from Baseline indicates improvement.
Timepoint [5] 0 0
Baseline and Week 24
Secondary outcome [6] 0 0
Change From Baseline in Fingernail-Physician Global Assessment (PGA-F)
Assessment method [6] 0 0
The PGA-F is a clinician-rated outcomes assessment used to measure the severity of signs and symptoms associated with fingernail psoriasis. Participant's fingernails were assessed separately for nail bed signs and nail matrix signs of disease on a scale from 0 (clear) to 4 (severe). A participant's overall global score is the worse of the nail bed score and nail matrix score. For example, if a participant had a nail bed score '2' and a nail matrix score of '4,' this participant's overall score was '4.' A negative change from Baseline indicates improvement.
Timepoint [6] 0 0
Baseline and Week 24
Secondary outcome [7] 0 0
Percentage of Participants With Resolution of Enthesitis at Week 24
Assessment method [7] 0 0
Resolution of enthesitis is defined as a Leeds Enthesitis Index (LEI) score = 0.

LEI is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions. Tenderness on examination is recorded as either present (coded as 1), absent (coded as 0), or not assessed for each of the 6 sites. The LEI is calculated by taking the sum of the scores from the 6 sites. The LEI ranges from 0 to 6 (worst).

To increase the sample size due to the smaller number of participants with enthesitis at Baseline, the pre-specified analysis of the resolution of enthesitis included pooled data from KEEPsAKE 1 (this study) and the companion study KEEPsAKE 2 (M15-998; NCT03671148).
Timepoint [7] 0 0
Week 24
Secondary outcome [8] 0 0
Percentage of Participants With Resolution of Dactylitis at Week 24
Assessment method [8] 0 0
Resolution of dactylitis is defined as a Leeds Dactylitis Index (LDI) score = 0.

LDI basic is a score based on finger circumference and tenderness, assessed across all digits. The LDI basic measures the ratio of the circumference of the affected digit to the circumference of the digit on the opposite hand or foot, using a minimum difference of 10% to define a dactylitic digit. The ratio of circumference is multiplied by a tenderness score (1 for tender, 0 for non-tender). If both sides of a digit are considered involved, or the circumference of the contralateral digit cannot be obtained, a standard reference table is used. Scores from each digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.

To increase sample size due to the smaller number of participants with dactylitis at Baseline, the pre-specified analysis of the resolution of dactylitis included pooled data from KEEPsAKE 1 (this study) and the companion study KEEPsAKE 2 (M15-998; NCT03671148).
Timepoint [8] 0 0
Week 24
Secondary outcome [9] 0 0
Change From Baseline in PsA Modified Total Sharp Score (mTSS) at Week 24
Assessment method [9] 0 0
The Sharp-van der Heijde modified scoring method for PsA measures the level of joint damage from radiographs of the hands and feet, and was assessed by 2 independent, blinded readers.

Joint erosion severity was assessed in 20 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 320 (worst).

Joint space narrowing (JSN) was assessed in 20 joints of each hand and wrist, and 6 joints of each foot, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 208 (worst).

Joints with gross osteolysis or pencil in cup were assigned the maximum score for both erosions and JSN.

The total mTSS score is the sum of the joint erosion and JSN scores and ranges from 0 (normal) to 528 (worst).
Timepoint [9] 0 0
Baseline and Week 24
Secondary outcome [10] 0 0
Change From Baseline In 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
Assessment method [10] 0 0
The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).

The physical component summary is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The SF-36 PCS ranges from 0 to 100. A linear algorithm was applied to the calculation of the PCS which has a normative mean value of 50. Higher scores are associated with less disability; a score of 100 is equivalent to no disability and a score of 0 is equivalent to maximum disability. A positive change from Baseline score indicates improvement.
Timepoint [10] 0 0
Baseline and Week 24
Secondary outcome [11] 0 0
Change From Baseline In Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24
Assessment method [11] 0 0
The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 (not at all) to 4 (very much).

The FACIT-Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue score ranges from 0 to 52, where higher scores represent less fatigue.

A positive change from Baseline indicates improvement.
Timepoint [11] 0 0
Baseline and Week 24
Secondary outcome [12] 0 0
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 24
Assessment method [12] 0 0
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria:

1. = 50% improvement in 68-tender joint count;
2. = 50% improvement in 66-swollen joint count; and
3. = 50% improvement in at least 3 of the 5 following parameters:

* Physician global assessment of disease activity
* Patient global assessment of disease activity
* Patient assessment of pain
* Health Assessment Questionnaire - Disability Index (HAQ-DI)
* High-sensitivity C-reactive protein (hsCRP).
Timepoint [12] 0 0
Baseline and Week 24
Secondary outcome [13] 0 0
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 24
Assessment method [13] 0 0
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria:

1. = 70% improvement in 68-tender joint count;
2. = 70% improvement in 66-swollen joint count; and
3. = 70% improvement in at least 3 of the 5 following parameters:

* Physician global assessment of disease activity
* Patient global assessment of disease activity
* Patient assessment of pain
* Health Assessment Questionnaire - Disability Index (HAQ-DI)
* High-sensitivity C-reactive protein (hsCRP).
Timepoint [13] 0 0
Baseline and Week 24

Eligibility
Key inclusion criteria
* Clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for PsA (CASPAR) at the Screening Visit.
* Participant has active disease at Baseline defined as = 5 tender joints (based on 68 joint counts) and = 5 swollen joints (based on 66 joint counts)
* Diagnosis of active plaque psoriasis with at least one psoriatic plaque of = 2 cm diameter or nail changes consistent with psoriasis at Screening Visit.
* Participant has demonstrated an inadequate response or intolerance to or contraindication for conventional synthetic disease modifying anti-rheumatic drugs (csDMARD) therapy(ies).
* Presence of either at Screening:

* = 1 erosion on radiograph as determined by central imaging review or;
* High sensitivity C-reactive protein (hsCRP) = 3.0 mg/L.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participant is considered by investigator, for any reason, to be an unsuitable candidate for the study.
* Participant has a known hypersensitivity to risankizumab.
* Participant has previous treatment with biologic agent.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,QLD,SA,VIC
Recruitment hospital [1] 0 0
The Canberra Hospital /ID# 207592 - Garran
Recruitment hospital [2] 0 0
Royal Brisbane and Women's Hospital /ID# 212785 - Herston
Recruitment hospital [3] 0 0
Rheumatology Research Unit Sunshine Coast /ID# 207200 - Maroochydore
Recruitment hospital [4] 0 0
Griffith University /ID# 207505 - Southport
Recruitment hospital [5] 0 0
Flinders Medical Centre /ID# 210562 - Bedford, Park
Recruitment hospital [6] 0 0
Emeritus Research /ID# 207202 - Camberwell
Recruitment hospital [7] 0 0
Monash Medical Centre /ID# 208034 - Clayton
Recruitment postcode(s) [1] 0 0
2605 - Garran
Recruitment postcode(s) [2] 0 0
4029 - Herston
Recruitment postcode(s) [3] 0 0
4558 - Maroochydore
Recruitment postcode(s) [4] 0 0
4222 - Southport
Recruitment postcode(s) [5] 0 0
5042 - Bedford, Park
Recruitment postcode(s) [6] 0 0
3124 - Camberwell
Recruitment postcode(s) [7] 0 0
3168 - Clayton
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Montana
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
United States of America
State/province [23] 0 0
West Virginia
Country [24] 0 0
United States of America
State/province [24] 0 0
Wisconsin
Country [25] 0 0
Argentina
State/province [25] 0 0
Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Ciuadad Autonoma De Buenos Aires
Country [27] 0 0
Argentina
State/province [27] 0 0
Santa Fe
Country [28] 0 0
Argentina
State/province [28] 0 0
Tucuman
Country [29] 0 0
Argentina
State/province [29] 0 0
Cordoba
Country [30] 0 0
Argentina
State/province [30] 0 0
San Miguel de Tucuman
Country [31] 0 0
Belgium
State/province [31] 0 0
Oost-Vlaanderen
Country [32] 0 0
Belgium
State/province [32] 0 0
Genk
Country [33] 0 0
Belgium
State/province [33] 0 0
Merksem
Country [34] 0 0
Bosnia and Herzegovina
State/province [34] 0 0
Republika Srpska
Country [35] 0 0
Bosnia and Herzegovina
State/province [35] 0 0
Sarajevo
Country [36] 0 0
Brazil
State/province [36] 0 0
Bahia
Country [37] 0 0
Brazil
State/province [37] 0 0
Minas Gerais
Country [38] 0 0
Brazil
State/province [38] 0 0
Parana
Country [39] 0 0
Brazil
State/province [39] 0 0
Rio Grande Do Sul
Country [40] 0 0
Brazil
State/province [40] 0 0
Sao Paulo
Country [41] 0 0
Bulgaria
State/province [41] 0 0
Pleven
Country [42] 0 0
Bulgaria
State/province [42] 0 0
Sofia
Country [43] 0 0
Canada
State/province [43] 0 0
British Columbia
Country [44] 0 0
Canada
State/province [44] 0 0
Manitoba
Country [45] 0 0
Canada
State/province [45] 0 0
Ontario
Country [46] 0 0
Canada
State/province [46] 0 0
Quebec
Country [47] 0 0
Canada
State/province [47] 0 0
Saskatchewan
Country [48] 0 0
Chile
State/province [48] 0 0
Providencia
Country [49] 0 0
Chile
State/province [49] 0 0
Santiago
Country [50] 0 0
Chile
State/province [50] 0 0
Vitacura Santiago
Country [51] 0 0
Croatia
State/province [51] 0 0
Grad Zagreb
Country [52] 0 0
Croatia
State/province [52] 0 0
Osjecko-baranjska Zupanija
Country [53] 0 0
Croatia
State/province [53] 0 0
Primorsko-goranska Zupanija
Country [54] 0 0
Croatia
State/province [54] 0 0
Splitsko-dalmatinska Zupanija
Country [55] 0 0
Croatia
State/province [55] 0 0
Zagreb
Country [56] 0 0
Czechia
State/province [56] 0 0
Brno
Country [57] 0 0
Czechia
State/province [57] 0 0
Praha
Country [58] 0 0
Czechia
State/province [58] 0 0
Uherske Hradiste
Country [59] 0 0
Denmark
State/province [59] 0 0
Hovedstaden
Country [60] 0 0
Denmark
State/province [60] 0 0
Midtjylland
Country [61] 0 0
Estonia
State/province [61] 0 0
Harjumaa
Country [62] 0 0
Estonia
State/province [62] 0 0
Tartumaa
Country [63] 0 0
Finland
State/province [63] 0 0
Uusimaa
Country [64] 0 0
Finland
State/province [64] 0 0
Kuopio
Country [65] 0 0
Finland
State/province [65] 0 0
Turku
Country [66] 0 0
Germany
State/province [66] 0 0
Nordrhein-Westfalen
Country [67] 0 0
Germany
State/province [67] 0 0
Berlin-buch
Country [68] 0 0
Germany
State/province [68] 0 0
Frankfurt
Country [69] 0 0
Germany
State/province [69] 0 0
Hamburg
Country [70] 0 0
Greece
State/province [70] 0 0
Attiki
Country [71] 0 0
Greece
State/province [71] 0 0
Kriti
Country [72] 0 0
Greece
State/province [72] 0 0
Thessaloniki
Country [73] 0 0
Greece
State/province [73] 0 0
Athens
Country [74] 0 0
Greece
State/province [74] 0 0
Patras
Country [75] 0 0
Israel
State/province [75] 0 0
Tel-Aviv
Country [76] 0 0
Israel
State/province [76] 0 0
Ashkelon
Country [77] 0 0
Israel
State/province [77] 0 0
Haifa
Country [78] 0 0
Israel
State/province [78] 0 0
Kfar Saba
Country [79] 0 0
Israel
State/province [79] 0 0
Petakh Tikva
Country [80] 0 0
Italy
State/province [80] 0 0
Emilia-Romagna
Country [81] 0 0
Italy
State/province [81] 0 0
Ancona
Country [82] 0 0
Italy
State/province [82] 0 0
Catania
Country [83] 0 0
Italy
State/province [83] 0 0
Rome
Country [84] 0 0
Italy
State/province [84] 0 0
Verona
Country [85] 0 0
Korea, Republic of
State/province [85] 0 0
Seoul Teugbyeolsi
Country [86] 0 0
Korea, Republic of
State/province [86] 0 0
Daegu
Country [87] 0 0
Latvia
State/province [87] 0 0
Adazi
Country [88] 0 0
Latvia
State/province [88] 0 0
Liepaja
Country [89] 0 0
Latvia
State/province [89] 0 0
Riga
Country [90] 0 0
Lithuania
State/province [90] 0 0
Kaunas
Country [91] 0 0
Lithuania
State/province [91] 0 0
Klaipeda
Country [92] 0 0
Lithuania
State/province [92] 0 0
Siauliai
Country [93] 0 0
Malaysia
State/province [93] 0 0
Negeri Sembilan
Country [94] 0 0
Malaysia
State/province [94] 0 0
Perak
Country [95] 0 0
Malaysia
State/province [95] 0 0
Selangor
Country [96] 0 0
Malaysia
State/province [96] 0 0
Kuala Lumpur
Country [97] 0 0
Mexico
State/province [97] 0 0
Ciudad De Mexico
Country [98] 0 0
Mexico
State/province [98] 0 0
Jalisco
Country [99] 0 0
Mexico
State/province [99] 0 0
Nuevo Leon
Country [100] 0 0
Mexico
State/province [100] 0 0
Yucatan
Country [101] 0 0
Mexico
State/province [101] 0 0
Ciudad de Mexico
Country [102] 0 0
Mexico
State/province [102] 0 0
Mexico City
Country [103] 0 0
Netherlands
State/province [103] 0 0
Fryslan
Country [104] 0 0
Netherlands
State/province [104] 0 0
Groningen
Country [105] 0 0
Netherlands
State/province [105] 0 0
Leeuwarden
Country [106] 0 0
New Zealand
State/province [106] 0 0
Auckland
Country [107] 0 0
New Zealand
State/province [107] 0 0
Waikato
Country [108] 0 0
New Zealand
State/province [108] 0 0
Burwood
Country [109] 0 0
Poland
State/province [109] 0 0
Kujawsko-pomorskie
Country [110] 0 0
Poland
State/province [110] 0 0
Malopolskie
Country [111] 0 0
Poland
State/province [111] 0 0
Mazowieckie
Country [112] 0 0
Poland
State/province [112] 0 0
Podlaskie
Country [113] 0 0
Poland
State/province [113] 0 0
Warminsko-mazurskie
Country [114] 0 0
Portugal
State/province [114] 0 0
Porto
Country [115] 0 0
Portugal
State/province [115] 0 0
Viana Do Castelo
Country [116] 0 0
Portugal
State/province [116] 0 0
Aveiro
Country [117] 0 0
Portugal
State/province [117] 0 0
Braga
Country [118] 0 0
Portugal
State/province [118] 0 0
Lisboa
Country [119] 0 0
Puerto Rico
State/province [119] 0 0
San Juan
Country [120] 0 0
Romania
State/province [120] 0 0
Timis
Country [121] 0 0
Romania
State/province [121] 0 0
Bucuresti
Country [122] 0 0
Romania
State/province [122] 0 0
Cluj-Napoca
Country [123] 0 0
Romania
State/province [123] 0 0
Iasi
Country [124] 0 0
Russian Federation
State/province [124] 0 0
Moskva
Country [125] 0 0
Russian Federation
State/province [125] 0 0
Novosibirskaya Oblast
Country [126] 0 0
Russian Federation
State/province [126] 0 0
Sankt-Peterburg
Country [127] 0 0
Russian Federation
State/province [127] 0 0
Tatarstan, Respublika
Country [128] 0 0
Russian Federation
State/province [128] 0 0
Moscow
Country [129] 0 0
Russian Federation
State/province [129] 0 0
Perm
Country [130] 0 0
Russian Federation
State/province [130] 0 0
Ulyanovsk
Country [131] 0 0
Serbia
State/province [131] 0 0
Beograd
Country [132] 0 0
Serbia
State/province [132] 0 0
Vojvodina
Country [133] 0 0
Singapore
State/province [133] 0 0
Singapore
Country [134] 0 0
Slovakia
State/province [134] 0 0
Biely Kostol
Country [135] 0 0
Slovakia
State/province [135] 0 0
Martin
Country [136] 0 0
Slovakia
State/province [136] 0 0
Nove Mesto nad Vahom
Country [137] 0 0
Slovakia
State/province [137] 0 0
Piestany
Country [138] 0 0
Slovakia
State/province [138] 0 0
Poprad
Country [139] 0 0
South Africa
State/province [139] 0 0
Eastern Cape
Country [140] 0 0
South Africa
State/province [140] 0 0
Gauteng
Country [141] 0 0
South Africa
State/province [141] 0 0
Western Cape
Country [142] 0 0
Spain
State/province [142] 0 0
Barcelona
Country [143] 0 0
Spain
State/province [143] 0 0
A Coruna
Country [144] 0 0
Spain
State/province [144] 0 0
Almeria
Country [145] 0 0
Spain
State/province [145] 0 0
Madrid
Country [146] 0 0
Spain
State/province [146] 0 0
Valencia
Country [147] 0 0
Sweden
State/province [147] 0 0
Orebro Lan
Country [148] 0 0
Sweden
State/province [148] 0 0
Skane Lan
Country [149] 0 0
Sweden
State/province [149] 0 0
Falun
Country [150] 0 0
Sweden
State/province [150] 0 0
Solna
Country [151] 0 0
Sweden
State/province [151] 0 0
Uppsala
Country [152] 0 0
Sweden
State/province [152] 0 0
Vasteras
Country [153] 0 0
Taiwan
State/province [153] 0 0
Chia-Yi
Country [154] 0 0
Taiwan
State/province [154] 0 0
Taichung
Country [155] 0 0
Taiwan
State/province [155] 0 0
Taoyuan City
Country [156] 0 0
Ukraine
State/province [156] 0 0
Kharkivska Oblast
Country [157] 0 0
Ukraine
State/province [157] 0 0
Vinnytska Oblast
Country [158] 0 0
Ukraine
State/province [158] 0 0
Cherkasy
Country [159] 0 0
Ukraine
State/province [159] 0 0
Chernihiv
Country [160] 0 0
Ukraine
State/province [160] 0 0
Kharkiv
Country [161] 0 0
Ukraine
State/province [161] 0 0
Khmelnytskyi
Country [162] 0 0
Ukraine
State/province [162] 0 0
Kryvyi Rih
Country [163] 0 0
Ukraine
State/province [163] 0 0
Kyiv
Country [164] 0 0
Ukraine
State/province [164] 0 0
Lutsk
Country [165] 0 0
Ukraine
State/province [165] 0 0
Lviv
Country [166] 0 0
Ukraine
State/province [166] 0 0
Poltava
Country [167] 0 0
Ukraine
State/province [167] 0 0
Zaporizhzhia
Country [168] 0 0
United Kingdom
State/province [168] 0 0
London, City Of
Country [169] 0 0
United Kingdom
State/province [169] 0 0
Scotland
Country [170] 0 0
United Kingdom
State/province [170] 0 0
Staffordshire
Country [171] 0 0
United Kingdom
State/province [171] 0 0
Manchester
Country [172] 0 0
United Kingdom
State/province [172] 0 0
Portsmouth
Country [173] 0 0
United Kingdom
State/province [173] 0 0
Torquay
Country [174] 0 0
United Kingdom
State/province [174] 0 0
Wirral

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
When will data be available (start and end dates)?
For details on when studies are available for sharing, please refer to the link below.
Available to whom?
Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://vivli.org/ourmember/abbvie/


What supporting documents are/will be available?

Results publications and other study-related documents

TypeCitations or Other Details
Journal Kristensen LE, Keiserman M, Papp K, McCasland L, W... [More Details]